Objective: To define the molecular basis of the autosomal dominant progressive external ophthalmoplegia and parkinsonism in a large family with a dominantly transmitted multiple mitochondrial DNA deletion disorder.
T H E P O L Y M E R A S E ␥ -1 (POLG1) gene codes for the m i t o c h o n d r i a l D N A
(mtDNA) polymerase ␥ (polγ), which has DNA polymerase and exonuclease activity. 1 Pathogenic POLG1 mutations were first described in autosomal dominant and recessive progressive external ophthalmoplegia (PEO) 2 and more recently in recessive late-onset ataxia with peripheral neuropathy 3, 4 and Alpers-Huttenlocher syndrome. [5] [6] [7] In a number of dominant pedigrees, parkinsonism appeared to segregate with PEO and a heterozygous pathogenic mutation in POLG1 and responded to levodopa treatment. 8 Positron emission tomographic imaging revealed a nigrostriatal dopaminergic deficit, and postmortem examination revealed neuronal loss in the substantia nigra but no Lewy bodies. 8 Parkinsonism has also been described in 2 other families with autosomal dominant PEO, with the movement disorder preceding the PEO in 1 subject, 9 and in 2 sisters with parkinsonism and peripheral neuropathy but no PEO. 10 To date, all of the subjects with PEO and parkinsonism had dominant heterozygous mutations affecting the polymerase domain of the polγ, but not all family members carrying the mutation developed extrapyramidal features, raising the possibility that additional genetic or environmental factors modulated the phenotype.
METHODS

PATIENTS
Our index case, II:8, was a 61-year-old woman who developed ptosis in her early 40s, followed by limb ataxia and progressive hearing loss. On examination, she had prominent ptosis, mild bilateral facial weakness, symmetric hip flexion weakness, and absent lower limb tendon reflexes with a mild gait ataxia. Figure 1A) . Respiratory chain complex analysis identified a combined defect of complex I, III, and IV. Southern blotting identified multiple deletions of skeletal muscle mtDNA ( Figure 1B) .
Her 52-year-old son (III:2) presented with fatigue and was noted to have bilateral ptosis since the age of 46 years. He subsequently developed an unsteady gait, progressive deafness, and dysphagia. Extrapyramidal features were first noted 2 years later, at age 48 years, and they progressed until his symptoms improved after receiving ropinirole. He had a history of depression. On examination, he walked with a stooped posture and a shuffling gait with limited arm-swing, slow turning, and postural instability. He had symmetric bradykinesia but no tremor. He had an expressionless face and hypophonia with bilateral ptosis and ophthalmoplegia with relative sparing of downgaze. There were mild symmetric proximal muscle weakness (Medical Research Council grade 4ϩ), absent lower limb reflexes, and mild gait ataxia. Investigations found normal serum creatine kinase (159 U/L), fasting glucose (88.27 mg/dL [4.9 mmol/L]), and lactate levels (18.02 mg/dL [2.0 mmol/L]). An electrocardiogram, respiratory function tests, and overnight oximetry had normal results. Muscle biopsy revealed an increase in muscle fiber diameters and an excess of internal nuclei. Fifteen percent of the muscle fibers were cytochrome c oxidase-deficient and 5% showed subsarcolemmal accumulation of mitochondria. A DaT (dopamine transporter) scan showed reduced uptake in both putamen and the left caudate nucleus ( Figure 1C ).
OTHER FAMILY MEMBERS
The other family members were independently examined by 2 neurologists (A.M.S. and P.F.C.). The family described one man (I:1) who had an obvious bilateral ptosis that developed in later years. He died many years ago, preventing formal assessment. There was nothing to suggest he had parkinsonism.
Three individuals (II:1, 60 y; II:3, 65 y; II:4, 58 y) had bilateral ptosis but were otherwise asymptomatic. Neurological examination was otherwise normal. Two individuals (II:5, 68 y; II:6, 69 y) had no relevant symptoms and normal neurological examination findings.
A 30-year-old woman (III:1) developed progressive bilateral ptosis in her early 20s followed by external ophthalmoplegia. She came to medical attention through an infertility clinic investigating her primary ovarian failure. A 50-year-old woman (III:3) had no relevant symptoms and normal neurological examination findings.
NUCLEAR DNA ANALYSIS
POLG1 was initially screened using denaturing highperformance liquid chromatography (Transgenomic, Omaha, Neb) as described. 11 The progressive external ophthalmoplegia 1 (PEO1) and adenine nucleotide translocator 1 (ANT1) genes were sequenced using a fluorescent chain terminating sequencing kit (Beckman Coulter Quickstart, Beckman Coulter CEQ 8000; Beckman Coulter, Fullerton, Calif). 12 Microsatellite analysis using markers flanking POLG1, PEO1, and ANT1 was performed using part of the 9cM Cooperative Human Linkage Centre Weber Human Screening set (version 10aRG; Invitrogen, Carlsbad, Calif ) and sized using a Beckman Coulter CEQ 8000 fluorescent DNA analyzer. POLG1 was then sequenced directly as described. 12 The frequency of the sequence variants was determined in 96 control subjects and 140 cases fulfilling UK Parkinson Disease Society Brain Bank criteria for the diagnosis of PD 13 by direct sequencing of exons 7 and 8 of POLG1.
RESULTS
No heteroduplexes were identified by denaturing highperformance liquid chromatography analysis of POLG1 in III:2, who also had a wild-type sequence for PEO1 and ANT1. Haplotype analysis using microsatellite markers showed that affected individuals were discordant for the haplotypes flanking PEO1 and ANT1, but all affected individuals shared the same haplotype flanking POLG1 (Figure 2) . We therefore sequenced POLG1 in III:2 and identified 2 novel heterozygous coding region substitutions in exon 7 (1389GϾT) and 8 (1532GϾA) and a novel intronic variant (c.2070ϩ158GϾA) (Figure 3) . The entire coding region of POLG1 was sequenced in II:1, II:8, and III:3, and exons 7, 8 and intron 11 were sequenced in the other living family members shown in Figure 2 . All individuals with PEO harbored 1532GϾA and c.2070ϩ 158GϾA. Only III:2 and his unaffected sister (III:3) were found to have 1389GϾT. None of the novel sequence variants were found in 192 ethnically matched control chromosomes nor in 108 patients with PEO and 140 cases of sporadic PD.
COMMENT
We have identified 3 POLG1 substitutions in the same family. c.2070ϩ158GϾA in intron 11 is unlikely to have functional consequences because it is not predicted to alter splice sites for the flanking exons.
14 1532GϾA is pre- dicted to alter a highly conserved serine to asparagine (S511N) in the linker region of polγ ( Figure 3B ). This mutation was found in all affected individuals in phase with c.2070 ϩ 158GϾA and is thus likely to be the pathogenic mutation causing autosomal dominant PEO in this family. This substitution is close to a previously described POLG1 mutation (Q497H) 4 and was not found in controls. The c.1399GϾA (A467T) substitution also affects the linker domain of the polγ and has been described in an Austrian family with dominant PEO. 15 Although A467T is also found in healthy control subjects (0.69% of the British population, 95% confidence interval, 0.14-2.02), 12 functional studies have shown that it reduces polymerase activity to 5% of normal values. 15, 16 Our observations support previous observations of dominantly inherited ptosis cosegregating with a single heterozygous linker domain substitution. 15 Although we cannot completely rule out the possibility that 1532GϾA (S511N) is a rare polymorphism, this is unlikely because it was not seen in 192 control chromosomes, nor in 248 disease control subjects, including 140 patients with idiopathic Parkinson disease who fulfilled UK Parkinson Disease Society brain bank criteria. Intriguingly, the subject II:6 was also heterozygous for 1532GϾA (S511N) and remained unaffected at 69 years of age (examined by A.M.S. and P.F.C.). This demonstrates that dominant POLG1 mutations can remain clinically nonpenetrant, potentially explaining why some sporadic heterozygotes have no family history. 1389GϾT is predicted to alter a highly conserved leucine to phenylalanine (L463F), also in the linker domain of polγ close to A467T (Figure 3) . The unaffected sister of the proband (III:3) also harbored 1389GϾT (L463F), indicating that the substitution was transmitted from their father (II:7). Although we were unable to examine II:7, nor obtain DNA samples, he was not thought to have ptosis. Based on current evidence, it is therefore unlikely that 1389GϾT (L463F) can cause disease on its own.
Even within this small family, there is striking clinical variability. This raises the question: could 1389GϾT (L463F) be contributing to the phenotype in III:2 and specifically the parkinsonism? It would be premature to draw firm conclusions at this stage, and we hope that further clinical and functional studies will address this question. Although his symptoms improved on a dopamine agonist, he had no tremor and the extrapyramidal rigidity was symmetric-features that mitigate against a diagnosis of idiopathic Parkinson disease. Abnormal DaT scan imaging results ( Figure 1C ) have been described in parkinsonian patients with PEO. 8 Our observations provide further evidence that more than one mutation can be segregating in the same family. 12 This is remarkable given the apparent rarity of these substitutions in the general population. Mutations in mitochondrial DNA polymerase 1 (MIP1), the yeast homologue of POLG1, not only cause secondary mutations of mitochondrial DNA, but also induce higher rates of nuclear gene mutations. 17 Although the reasons for this are not clear, it may be related to oxidative stress related to the mitochondrial damage. 17 If correct, then it is conceivable that POLG1 mutations themselves lead to further mutation in this and other genes, which may also be transmitted down the germ line. This provides a potential mechanism for epistatic genetic interactions contributing to the variable phenotype of the disorder. 12 Neither 1389GϾT (L463F) nor 1532GϾA (S511N) directly affect the polymerase domain of polγ. Like other linker region mutations, they are, however, likely to affect polymerase activity of the enzyme. 15, 16 Progressive external ophthalmoplegia with parkinsonism can therefore be caused by mutations in both the linker and polymerase domain of polγ. 
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